Egrifta (Tesamorelin) at Work and in Daily Life: A Woman's Guide

What Egrifta Actually Does in Your Body

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds GHRH receptors in the pituitary, stimulating pulsatile secretion of endogenous growth hormone (GH), which then raises insulin-like growth factor-1 (IGF-1). The target effect is selective reduction of visceral adipose tissue (VAT) in people living with HIV who have developed lipodystrophy, a fat redistribution syndrome linked to antiretroviral therapy. The FDA approved tesamorelin (Egrifta) in 2010 specifically for this indication.

Unlike general GH therapy, tesamorelin works through the body's own feedback loop. IGF-1 rises, but the pituitary's negative-feedback mechanisms remain partially intact, which is one reason the metabolic side-effect profile differs from exogenous GH injections.

Why the GH Axis Matters Differently for Women

Women naturally secrete GH in a more pulsatile, higher-amplitude pattern than men across reproductive years, driven partly by estrogen. Estrogen upregulates GH receptor sensitivity in the liver and increases GH secretion. After menopause, baseline GH secretion declines sharply alongside estrogen. This means a woman's starting GH axis state, and therefore her IGF-1 response to tesamorelin, depends substantially on where she is in her hormonal life.

Data from the key LIPO-010 trial (Falutz et al., NEJM 2007) showed that tesamorelin 2 mg daily reduced VAT by a mean of 15.2% versus placebo at 26 weeks. That trial enrolled predominantly men; women represented fewer than 20% of participants. Sex-disaggregated results were not published in the primary report, which reflects the broader clinical trial evidence gap that affects women on this drug.

Your Daily Injection Routine: Practical Logistics for Working Women

The injection is once daily, typically at bedtime, and takes fewer than five minutes once you have the technique down. Choosing a consistent time matters because tesamorelin's GH-stimulating pulse aligns best with the nocturnal GH surge your body naturally produces during sleep.

Reconstitution and Timing

Egrifta SV (the current formulation) comes as a lyophilized powder that requires reconstitution with the supplied diluent. The prescribing label specifies that after mixing, the solution must be used within three hours and should not be refrigerated after reconstitution. For most women, this means mixing immediately before injection rather than preparing doses in advance.

If you work evening or night shifts, discuss timing with your prescriber. Injecting at the start of your longest sleep window, whatever time that falls, is the practical goal.

Storage at Work and While Traveling

Unmixed vials must stay refrigerated at 36 to 46°F (2 to 8°C). This creates a real daily-life consideration: you cannot leave your medication in a desk drawer or a gym bag. Options that work in practice include:

• A small medical-grade cooler for commuting or short travel
• Asking HR about refrigerator access in a private space (break room mini-fridge in a labeled case is standard)
• TSA allows prescription injectable medications in carry-on luggage; bring the original pharmacy label and a letter from your prescriber for international travel

The FDA label states vials may be kept at room temperature up to 77°F (25°C) for a maximum of three months before first use, so you have some flexibility during a domestic trip if you can keep the medication out of heat.

Injection Site Management for Women

The approved injection site is subcutaneous abdominal tissue. Women with higher abdominal adiposity from lipodystrophy may find injection easier in some areas, but also may have more variation in tissue depth. Rotate sites within the abdomen and avoid the two-inch ring around the navel, areas of visible scarring, or any skin that is bruised, irritated, or affected by other conditions.

Women who have had cesarean sections may have abdominal scar tissue that should be avoided. If you have had abdominoplasty or significant abdominal surgery, discuss anatomical site alternatives with your prescriber, though no alternative sites are formally approved.

Side Effects That Affect Your Work Day

Most side effects from tesamorelin are manageable, but several deserve specific attention for women who need to function professionally.

Joint Pain and Fluid Retention

In the LIPO-010 trial, arthralgia occurred in approximately 13% of tesamorelin recipients versus 5% on placebo. Peripheral edema appeared in about 6% versus 2% on placebo. For a woman who stands for long shifts, types for hours, or performs physical work, these are not trivial numbers.

Joint pain tends to peak in the first eight to twelve weeks and often improves without stopping the drug. Edema, when it occurs, is usually mild and resolves. If swelling becomes significant, a temporary dose reduction or pause is sometimes used off-label, though this should be clinician-directed.

Blood Glucose Effects

Tesamorelin raises GH, and GH is a counter-regulatory hormone that can impair insulin sensitivity. The prescribing information specifically flags the risk of glucose intolerance and new-onset diabetes. Women with PCOS already carry elevated insulin resistance and are a higher-risk subgroup, though this has not been studied directly in tesamorelin trials.

If you have PCOS, prediabetes, or a family history of type 2 diabetes, ask your prescriber about baseline and quarterly fasting glucose and hemoglobin A1c monitoring. The American Diabetes Association's standards of care recommend monitoring glucose changes with any GH-axis therapy.

On a practical level: if you feel shaky, unusually fatigued, or thirsty during your workday, check your blood glucose. These symptoms warrant same-day contact with your care team.

Carpal Tunnel Syndrome

GH elevation can cause fluid retention in soft tissues, including the carpal tunnel. Tingling, numbness, or pain in the hand and wrist while working, especially during prolonged keyboard use or repetitive tasks, should be reported. The symptom typically resolves with dose reduction or discontinuation. For women in office jobs or healthcare, this side effect is worth knowing about before it disrupts your capacity to work.

A practical three-tier framework for managing tesamorelin side effects at work:

Tier 1 (monitor, no action needed immediately): mild joint stiffness in the morning, slight ankle swelling at end of day, transient injection-site redness lasting under 24 hours.

Tier 2 (contact your prescriber within 48 hours): persistent wrist or hand numbness, swelling that is increasing week over week, fasting blood glucose above 126 mg/dL on home monitoring.

Tier 3 (same-day contact or urgent care): signs of glucose crisis, signs of pituitary insufficiency (severe headache, vision changes), allergic reaction (hives, throat tightness).

How Tesamorelin Interacts With Hormonal Medications Common in Women

Tesamorelin raises IGF-1, and IGF-1 clearance is modulated by estrogen status. Women on combined hormonal contraceptives, particularly high-dose estrogen formulations, may have blunted IGF-1 responses to GH-axis stimulation. This is a pharmacokinetic interaction recognized with exogenous GH therapy and is plausible with tesamorelin, though it has not been studied directly in tesamorelin trials.

A 2009 study in the Journal of Clinical Endocrinology & Metabolism found that oral estrogen significantly reduces IGF-1 levels compared with transdermal estrogen in GH-deficient women on replacement therapy. If you are on oral contraceptives or oral menopausal hormone therapy while taking tesamorelin, your IGF-1 response may be lower than expected. Transdermal estrogen forms (patch, gel, spray) do not carry the same hepatic first-pass effect and may interfere less.

This is a data gap worth naming plainly: no tesamorelin trial has enrolled women stratified by hormonal contraception type. The extrapolation from GH-deficiency data is reasonable but not proven.

Life Stage Considerations: Reproductive Years Through Postmenopause

Women in Reproductive Years on ART

HIV-positive women of reproductive age on antiretroviral therapy (ART) represent the intended clinical population for tesamorelin. Lipodystrophy in this group often affects the abdomen, leading to visible body changes that affect self-image, clothing fit, and workplace confidence. Women report that abdominal fat accumulation from lipodystrophy contributes to social stigma and affects willingness to disclose HIV status.

Real-world evidence from the Canadian HIV Women's Sexual and Reproductive Health Cohort Study (CHIWOS) documents that body image concerns are among the top quality-of-life issues for women living with HIV. Tesamorelin addresses this directly, with a mean VAT reduction of 15.2% at 26 weeks in the LIPO-010 trial, and some evidence of continued reduction with 52-week use.

Perimenopause

Perimenopausal women have fluctuating estrogen and progesterone that already disrupts GH pulsatility. Adding tesamorelin to this hormonal context is largely unstudied. Menopausal transition also brings its own insulin resistance and central fat accumulation, which can overlap with and complicate lipodystrophy assessment.

The Menopause Society (formerly NAMS) notes that the average woman gains 1.5 kg during the perimenopausal transition, with preferential accumulation of visceral fat. Distinguishing this from HIV-related lipodystrophy requires clinical judgment and, ideally, abdominal CT imaging rather than BMI alone.

Postmenopause

GH secretion is substantially lower in postmenopausal women than in premenopausal women. If your GH axis is already suppressed by age and estrogen loss, the stimulatory effect of tesamorelin may be proportionally smaller, though this has not been confirmed in trials. IGF-1 monitoring becomes especially useful in this group to verify that the drug is having a measurable effect.

Postmenopausal women on tesamorelin should also be aware that IGF-1 elevation has been associated with increased breast tissue proliferation in some research contexts. The prescribing label does not currently list breast cancer as a contraindication, but women with a personal or strong family history of hormone-sensitive breast cancer should have a detailed conversation with their oncologist and HIV specialist before starting.

Pregnancy, Lactation, and Contraception: Required Reading

Pregnancy

Tesamorelin is contraindicated during pregnancy. The FDA prescribing label classifies it as FDA Pregnancy Category X, meaning animal studies have demonstrated fetal harm and the risks outweigh any potential benefit. In animal reproductive studies, tesamorelin caused fetal growth restriction and embryotoxicity.

If you become pregnant while taking Egrifta, stop the medication immediately and contact your prescriber and your HIV care team the same day. Pregnancy management in women living with HIV requires rapid adjustment of ART regimens, and adding a contraindicated peptide hormone to that equation increases complexity.

Because tesamorelin is used in women of reproductive age, contraception is not optional. Use a reliable, highly effective contraceptive method while on tesamorelin. IUDs (hormonal or copper) are appropriate and do not carry the oral estrogen interaction concern. If you use combined oral contraceptives for contraception, discuss with your prescriber whether this may reduce your tesamorelin IGF-1 response and whether a progestin-only or non-hormonal method is preferable.

Lactation

There are no human data on tesamorelin transfer into breast milk. Given its peptide structure, it would likely be partially degraded in the infant's gastrointestinal tract, but this has not been studied. The FDA label recommends against use during breastfeeding. For women living with HIV in resource-adequate settings, CDC guidelines already recommend formula feeding to prevent vertical HIV transmission, so the breastfeeding contraindication for tesamorelin generally aligns with existing HIV guidance.

If you are in the postpartum period and considering restarting tesamorelin, confirm with your care team that you are not lactating before resuming.

Who This Is Right For and Who Should Pause

Women Likely to Benefit

• HIV-positive women on stable ART who have documented VAT excess confirmed by imaging or clinical assessment
• Women with significant body image distress from abdominal lipodystrophy affecting quality of life or work
• Women whose lipodystrophy is causing metabolic risk (elevated triglycerides, insulin resistance) attributable to visceral fat

Women Who Should Not Use Tesamorelin or Should Use It With Extra Caution

• Pregnant women or those actively trying to conceive
• Women with active malignancy; GH-axis stimulation is contraindicated with active cancer
• Women with hypopituitarism or hypothalamic injury; the drug requires an intact pituitary
• Women with pre-existing carpal tunnel syndrome that is already symptomatic
• Postmenopausal women with a personal history of hormone-sensitive breast cancer (discuss with oncologist)
• Women with poorly controlled diabetes; glucose must be stable before starting

"Tesamorelin should be discontinued in patients who develop diabetes mellitus, as the drug's GH-stimulating effects may worsen glycemic control," states the Egrifta SV prescribing information.

Monitoring Schedule That Fits Around Your Life

Your prescriber should track the following at intervals that are predictable enough to schedule around work:

| Test | Baseline | 3 months | 6 months | Annually | |---|---|---|---|---| | Fasting glucose / HbA1c | Yes | Yes | Yes | Yes | | IGF-1 | Yes | Yes | Yes | Yes | | Fasting lipid panel | Yes | No | Yes | Yes | | Abdominal CT or waist circumference | Yes | No | Yes | Yes | | Thyroid function | Yes | No | No | Yes |

IGF-1 should be kept within age- and sex-specific normal ranges. If IGF-1 rises above the upper limit of normal, your prescriber should reduce the dose. Supraphysiologic IGF-1 sustained over time is the marker for risk of the GH-related complications listed in the label.

"The goal of tesamorelin therapy is physiologic IGF-1 restoration, not supraphysiologic stimulation," as stated in Falutz et al., NEJM 2007, reflecting the trial's monitoring rationale.

Talking to Your Employer and HR: Practical Points

You do not have to disclose your HIV status or the specific indication for tesamorelin to your employer. You are entitled to reasonable accommodation for medication storage and administration under ADA guidelines.

Asking for refrigerator access for a temperature-sensitive prescription medication, or requesting a private space for a brief daily injection, is a reasonable accommodation request. You do not need to name the drug or condition. A letter from your prescriber stating you require refrigerated storage for a daily injectable medication is typically sufficient.

If your work involves physical demands and you develop significant joint pain or edema, an accommodation request for modified duties during the first eight to twelve weeks of therapy is also reasonable. Most joint symptoms improve without stopping the drug, so a temporary modification often bridges the adaptation period.

Stopping Egrifta: What Happens to Your Body and Daily Life

VAT returns toward pre-treatment levels after stopping tesamorelin. In the extension phase of the LIPO-010 trial, patients who discontinued active drug and switched to placebo regained a significant portion of their visceral fat reduction within 26 weeks. This is not unique to tesamorelin; it reflects the nature of a drug that works through an ongoing hormonal signal.

Stopping the drug does not cause acute withdrawal in the classical sense, because you are not replacing a hormone your body cannot make. The pituitary resumes its pre-treatment GH secretion pattern. Glucose levels and IGF-1 normalize within weeks. Joint symptoms and edema resolve.

If you need to stop for a planned pregnancy, you should stop tesamorelin as soon as you begin trying to conceive, not only after a positive test.